|
|
|
| Research progress of radical prostatectomy in patients with metastatic prostate cancer |
| ZHANG Chongjian1 BAI Yu2 |
1.Graduate School, Kunming Medical University, Yunnan Province, Kunming 650100, China;
2.Department of Urology, the Third Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650100, China |
|
|
|
Abstract Radical prostatectomy has always been the main treatment for early prostate cancer. For metastatic prostate cancer (mPCa), most conservative treatments such as endocrine therapy are used. In recent years, with the deep understanding of the mechanism of prostate cancer and the continuous advancement of surgical techniques, the role of surgery in mPCa has gradually been recognized by some scholars. It is now systematically reviewed that the current status of prostatectomy in patients with mPCa through clinical research analysis and basic biological research, and prospects for future research.
|
|
|
|
|
|
[1] Veeratterapillay R，Goonewardene SS，Barclay J，et al. Radical prostatectomy for locally advanced and metastatic prostate cancer [J]. Ann R Coll Surg Engl，2017，99（4）：259-264.
[2] 韩苏军，张思维，陈万青，等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志，2013，18（4）：330-334.
[3] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA-Cancer J Clin，2016，66（2）：115-132.
[4] 张凯.中国前列腺癌外科治疗专家共识[J].浙江医学，2018，40（3）：217-220.
[5] Won AC，Gurney H，Marx G，et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer [J]. BJU Int，2013，112（4）：E250-E255.
[6] Gratzke C，Engel J，Stief CG. Role of radical prostatectomy in metastatic prostate cancer：data from the Munich Cancer Registry [J]. Eur Urol，2014，66（3）：602-603.
[7] Culp SH，Schellhammer PF，Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor A SEER-based study [J]. Eur Urol，2014，65（6）：1058-1066.
[8] Fossati N，Trinh QD，Sammon J，et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer：a SEER-based study [J]. Eur Urol，2015，67（1）：3-6.
[9] Gandaglia G，Fossati N，Montorsi F，et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer：Results of a Single-institution Series with Long-term Follow-up [J]. Eur Urol，2017，72（2）：e31.
[10] Heidenreich A，Pfister D，Brehmer B，et al. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases：results of a first feasibility and case control study] [J]. Urologe A，2015，54（1）：14-21.
[11] Sooriakumaran P，Nyberg T，Akre O，et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer：observational study of mortality outcomes [J]. BMJ，2014，348：g1502.
[12] Sooriakumaran P，Karnes J，Stief C，et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Met-astatic Prostate Cancer at Presentation [J]. Eur Urol，2016， 69（5）：788-794.
[13] Messing EM，Manola J，Yao J，et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy [J]. Lancet Oncol，2006，7（6）：472-479.
[14] Steuber T，Budaus L，Walz J，et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era： a confirmatory study [J]. BJU Int，2011，107（11）：1755-1761.
[15] Wang Y，Qin Z，Wang Y，et al. The role of radical prostatectomy for the treatment of metastatic prostate cancer：a systematic review and meta-analysis [J]. Biosci Rep，2018，38（1）. pii: BSR20171379.
[16] Qin XJ，Ma CG，Ye DW，et al. Tumor cytoreduction results in better response to androgen ablation-a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer [J]. Urol Oncol，2012，30（2）：145-149.
[17] Steuber T，Berg KD，Roder MA，et al. Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study [J]. Eur Urol Focus，2017，3（6）：646-649.
[18] Poelaert F，Verbaeys C，Rappe B，et al. Cytoreductive Prostatectomy for Metastatic Prostate Cancer：First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer（LoMP）Trial [J]. Urology，2017，106：146-152.
[19] Natarajan S，Raman S，Priester AM，et al. Focal Laser Ablation of Prostate Cancer：Phase I Clinical Trial [J]. J Urol，2016，196（1）：68-75.
[20] Hamdy FC，Elliott D，le Conte S，et al. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer：the PART feasibility RCT [J]. Health Technol Assess，2018，22（52）：1-96.
[21] Kim EH，Bullock AD. Surgical Management for Prostate Cancer [J]. Mo Med，2018，115（2）：142-145.
[22] Peacock M，Quirt J，James Morris W，et al. Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia [J]. Can Urol Assoc J，2015，9（11-12）：409-413.
[23] Abdollah F，Briganti A，Montorsi F，et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer：a population-based analysis [J]. Int J Urol，2013，20（5）：548-549.
[24] Psaila B，Lyden D. The metastatic niche：adapting the foreign soil [J]. Nat Rev Cancer，2009，9（4）：285-293.
[25] Bayne CE，Williams SB，Chapin BF，et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer：Current Concepts and Future Perspectives [J]. Eur Urol，2017，71（2）：e51.
[26] Kim MY，Oskarsson T，Acharyya S，et al. Tumor self-seeding by circulating cancer cells [J]. Cell，2009，139（7）：1315-1326. |
|
|
|
